Cargando…

Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a.

Combined chemo-/immunotherapy has shown high objective response rates and a significant though small proportion of long-term complete responders in metastatic malignant melanoma. The purpose of this study was to determine response rates, freedom from treatment failure (FFTF) and overall survival in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoffmann, R., Müller, I., Neuber, K., Lassmann, S., Buer, J., Probst, M., Oevermann, K., Franzke, A., Kirchner, H., Ganser, A., Atzpodien, J.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group\|1 1998
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063152/ https://www.ncbi.nlm.nih.gov/pubmed/9792153

Ejemplares similares

Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
por: Johnston, S. R., et al.
Publicado: (1998)

Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine
por: Propper, D J, et al.
Publicado: (2000)

Prognostic impact of in vivo soluble cell adhesion molecules in metastatic renal cell carcinoma
por: Hoffmann, R, et al.
Publicado: (1999)

Capecitabine in the treatment of metastatic renal cell carcinoma
por: Oevermann, K, et al.
Publicado: (2000)

Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma
por: Wittke, F, et al.
Publicado: (1999)

A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma
por: Middleton, M R, et al.
Publicado: (2000)

Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma.
por: Franzke, A., et al.
Publicado: (1998)

Elevated serum levels of S100 and survival in metastatic malignant melanoma.
por: Buer, J., et al.
Publicado: (1997)

Dacarbazine (DTIC) and human recombinant interferon alpha 2a (Roferon) in the treatment of disseminated malignant melanoma.
por: Mulder, N. H., et al.
Publicado: (1990)

Dacarbazine (DTIC), human recombinant interferon alpha 2a (Roferon) and 5-fluorouracil for disseminated malignant melanoma.
por: Mulder, N. H., et al.
Publicado: (1992)

Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen.
por: Henriksson, R., et al.
Publicado: (1998)

Advanced Gastric Carcinoma Chemotherapy with Cisplatin, Mitomycin C, BCNU, and 5-Fluorouracil in Combination
por: Kim, Re Hwe, et al.
Publicado: (1987)

Survival in renal cell carcinoma: a randomized evaluation of tamoxifen vs interleukin-2, α-interferon (leucocyte) and tamoxifen
Publicado: (2000)

Survival in renal cell carcinoma: a randomized evaluation of tamoxifen vs interleukin-2, α-interferon (leucocytic) and tamoxifen – reply
Publicado: (2000)

Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma.
por: Mulder, N. H., et al.
Publicado: (1994)

Rapid deterioration in quality of life during interleukin-2- and α-interferon-based home therapy of renal cell carcinoma is associated with a good outcome
por: Atzpodien, J, et al.
Publicado: (2003)

Safety and efficacy of carmustine (BCNU) wafers for metastatic brain tumors
por: Ene, Chibawanye I., et al.
Publicado: (2016)

CXCR4/CXCL12 expression and signalling in kidney cancer
por: Schrader, A J, et al.
Publicado: (2002)

Is Interstitial Chemotherapy with Carmustine (BCNU) Wafers Effective against Local Recurrence of Glioblastoma? A Pharmacokinetic Study by Measurement of BCNU in the Tumor Resection Cavity
por: Ohnishi, Takanori, et al.
Publicado: (2022)

Low dose DTIC is effective and safe in pretreated patients with well differentiated neuroendocrine tumors
por: Mueller, Daniela, et al.
Publicado: (2016)

In vitro potentiation of BCNU activity in rat brain tumour cells pretreated with misonidazole.
por: Siemann, D. W., et al.
Publicado: (1984)

In vivo response of KHT sarcomas to combination chemotherapy with radiosensitizers and BCNU.
por: Mulcahy, R. T., et al.
Publicado: (1981)

BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors
por: Reithmeier, Thomas, et al.
Publicado: (2010)

Identification of novel regulators in T-cell differentiation of aplastic anemia patients
por: Franzke, Anke, et al.
Publicado: (2006)

Sequential Combination Chemotherapy of Dacarbazine (DTIC) with Carboplatin and Paclitaxel for Patients with Metastatic Mucosal Melanoma of Nasal Cavity and Paranasal Sinuses
por: Omata, W., et al.
Publicado: (2017)

Diminished production of type-I interferons and interleukin-2 in patients with multiple sclerosis
por: Wandinger, Klaus-Peter, et al.
Publicado: (1997)

IL-2 in combination with IFN-αand 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial
por: Atzpodien, J, et al.
Publicado: (2001)

Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro.
por: Wedge, S. R., et al.
Publicado: (1996)

In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: cyclophosphamide and BCNU.
por: Tannock, I. F.
Publicado: (1980)

Interstitial chemotherapy with biodegradable BCNU (Gliadel(®)) wafers in the treatment of malignant gliomas
por: Bota, Daniela A, et al.
Publicado: (2007)

Symptomatic Remote Cyst after BCNU Wafer Implantation for Malignant Glioma
por: MATSUMURA, Hideaki, et al.
Publicado: (2018)

Importance of biomarkers in glioblastomas patients receiving local BCNU wafer chemotherapy
por: Urbschat, Steffi, et al.
Publicado: (2017)

DTIC xenogenized lines obtained from an L1210 clone: clonal analysis of cytotoxic T lymphocyte reactivity.
por: Marelli, O., et al.
Publicado: (1988)

Formation and loss of O6-methyldeoxyguanosine in human leucocyte DNA following sequential DTIC and fotemustine chemotherapy.
por: Lee, S. M., et al.
Publicado: (1994)

Inhibitors of GLUT/SLC2A Enhance the Action of BCNU and Temozolomide against High-Grade Gliomas
por: Azzalin, Alberto, et al.
Publicado: (2017)

Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients
por: Atzpodien, J, et al.
Publicado: (2007)

Interleukin 10 Secretion and Impaired Effector Function of Major Histocompatibility Complex Class II–restricted T Cells Anergized In Vivo
por: Buer, Jan, et al.
Publicado: (1998)

rhGM-CSF ameliorates neutropenia in patients with malignant glioma treated with BCNU.
por: Rampling, R., et al.
Publicado: (1994)

Daunorubicin and doxorubicin but not BCNU have deleterious effects on organotypic multicellular spheroids of gliomas.
por: Kaaijk, P., et al.
Publicado: (1996)

MLTI-11. IMPLANTABLE POLYMERIC BCNU AS AN ADJUNCT TO SURGERY FOR METASTATIC INTRACRANIAL DISEASE
por: Ryken, Timothy, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_oeggi2b5qmis1nheoegas935pr